Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Feb;38(1):1-3.
doi: 10.1007/s10557-024-07543-7. Epub 2024 Feb 6.

Dapagliflozin for Atrial Fibrillation

Na Li  1 , Mihail G Chelu  2 , Yochai Birnbaum  3
Affiliations
Editorial

Dapagliflozin for Atrial Fibrillation

Na Li et al. Cardiovasc Drugs Ther. 2024 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations

Conflict of Interest The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Schematic representation of the postulated mechanisms underlying the suppression of atrial fibrillation-promoting mechanisms mediated by an SGLT2 inhibitor. APD, action potential duration; AMPK, adenosine monophosphate kinase; DAD, delayed afterdepolarization; NCX, Na+/Ca2+ exchanger; NHE-1, Na+/H.+ exchanger-1; ROS, reactive oxygen species (Created with BioRender.com)
See this image and copyright information in PMC

References

    1. Zelniker TA, Bonaca MP, Furtado RHM, et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 Trial. Circulation. 2020;141(15):1227–34. 10.1161/CIRCULATIONAHA.119.044183. - DOI - PubMed
    1. Luo F, Sun L, Wang Z, et al. Effect of dapagliflozin on the outcome of radiofrequency catheter ablation in patients with type 2 diabetes mellitus and atrial fibrillation. Cardiovasc Drugs Ther. 2024;38(1). 10.1007/s10557-022-07368-2. - DOI - PubMed
    1. Kishima H, Mine T, Fukuhara E, et al. Efficacy of sodium-glucose cotransporter 2 inhibitors on outcomes after catheter ablation for atrial fibrillation. JACC Clin Electrophysiol. 2022;8(11):1393–404. 10.1016/j.jacep.2022.08.004. - DOI - PubMed
    1. Abu-Qaoud MR, Kumar A, Tarun T, et al. Impact of SGLT2 inhibitors on AF recurrence after catheter ablation in patients with type 2 diabetes. JACC Clin Electrophysiol. 2023;9(10):2109–18. 10.1016/j.jacep.2023.06.008. - DOI - PubMed
    1. Ye Y, Bajaj M, Yang HC, Perez-Polo JR, Birnbaum Y. SGLT-2 Inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc Drugs Ther. 2017;31(2):119–32. 10.1007/s10557-017-6725-2. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources